Allarity Therapeutics, Inc.
$1.38
The Read: Allarity Therapeutics' stock fell about 29% after Q2 2026 earnings due to no immediate clinical breakthroughs and a long trial timeline, but earlier in May 2026 it rose about 16% on positive updates about stenoparib’s FDA Fast Track status, new IP allowance, and solid cash reserves.
Price
Overlays
Panel
ALLR
Hover to view data
No Data